Dr. Sina Habibi reports
COGNETIVITY NEUROSCIENCES PUBLISHES KEY RESULTS FROM ITS INTEGRATED COGNITIVE ASSESSMENT RESEARCH IN NATURE PUBLISHING GROUP JOURNAL SCIENTIFIC REPORTS
The results from Cognetivity Neurosciences Ltd.'s research and development program into its integrated cognitive assessment (ICA) platform have been published in a leading peer-reviewed academic journal, Scientific Reports, from the publishers of Nature.
The paper describes results from key studies validating the effectiveness of the ICA's unique approach of using a rapid visual categorization task for detecting changes in cognitive performance and its potential for use in early detection of mental disorders, including dementia, and micromonitoring of cognitive performance.
Cognetivity's chief executive officer and director, Dr. Sina Habibi, commented: "We are delighted to announce this first peer-reviewed publication of our groundbreaking research in the area of cognitive performance measuring. Now that we have been granted patents covering key areas of our technology, we have been able to release details of our research and development program and some of the excellent results which validate our approach for our sensitive, repeatable and fully scalable solution to the early detection of conditions that involve cognitive impairment. It is our aim to make our technology available to help as many people as possible, whether through its use in clinical environments for the crucial early detection of conditions such as dementia or through allowing people to measure their ongoing cognitive performance in a meaningful way as part of their overall health monitoring activities."
About Cognetivity Neurosciences Ltd.
Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical and commercial environments. Cognetivity's ICA uses artificial intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.
We seek Safe Harbor.
© 2019 Canjex Publishing Ltd. All rights reserved.